Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

被引：0

作者：

Loree, Jonathan M.

Topham, James T.

Kennecke, Hagen Fritz

Feilotter, Harriet

Lee, Young S.

Virk, Shakeel

Kopetz, Scott

Duose, Dzifa Yawa

Manyam, Ganiraju C.

Morris, Jeffrey S.

Maru, Dipen M.

Renouf, Daniel

Jonker, Derek J.

Tu, Dongsheng

O'Callaghan, Christopher J.

Chen, Eric Xueyu

机构：

[1] Genome Sci Ctr, Vancouver, BC, Canada

[2] Providence Canc Inst, Portland, OR USA

[3] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada

[4] AstraZeneca, Translat Med, Gaithersburg, MD USA

[5] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA

[8] Univ Penn, Philadelphia, PA USA

[9] MD Anderson Canc Ctr, Houston, TX USA

[10] Univ British Columbia, Vancouver, BC, Canada

[11] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada

[12] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3551

引用

页数：1

共 50 条

[21] Final results from a phase III trial evaluating panitumumab (pmab) plus best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
Kim, Tae Won
Elme, Anneli
Kusic, Zvonko
Park, Joon Oh
Udrea, Anghel Adrian
Kim, Sun Young
Ahn, Joong Bae
Valencia, Ricardo Villalobos
Srinivasan, Krishnan
Bilic, Ante
Manojlovic, Nebojsa
Dong, Jun
Guan, Xuesong
Lofton-Day, Catherine
Jung, A. Scott
Vrdoljak, Eduard
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Panitumumab for the treatment of metastatic colorectal cancer (MCRC): A multi-center study in patients (PTS) who failed chemotherapy (CTX) and best supportive care (BSC).
Humblet, Yves
Van Cutsem, Eric
Peeters, Marc
Siena, Salvatore
Hendlisz, Alain
Neyns, Bart
Canon, Jean-Luc
Van Laethem, Jean-Luc
Maurel, Joan
Richardson, Gary
ANNALS OF ONCOLOGY, 2006, 17 : 114 - 114
[23] A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
Wang, J.
Zhao, Z.
Barber, B.
Sherrill, B.
Peeters, M.
Wiezorek, J.
BRITISH JOURNAL OF CANCER, 2011, 104 (12) : 1848 - 1853
[24] A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
J Wang
Z Zhao
B Barber
B Sherrill
M Peeters
J Wiezorek
British Journal of Cancer, 2011, 104 : 1848 - 1853
[25] Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
Ma, Lucy Xiaolu
Loree, Jonathan M.
Jonker, Derek J.
Kennecke, Hagen Fritz
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aucoin, Nathalie
Aubin, Francine
Koski, Sheryl L.
Tu, Dongsheng
O'Callaghan, Christopher J.
Chen, Eric Xueyu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 183 - 183
[26] A Q-TWIST ANALYSIS COMPARING PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) WITH BSC ALONE IN PATIENTS WITH WILD-TYPE KRAS METASTATIC COLORECTAL CANCER
Wang, J.
Zhao, Z.
Sherrill, B.
Peeters, M.
Wiezorek, J.
Barber, B.
VALUE IN HEALTH, 2011, 14 (03) : A170 - A170
[27] A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
Tae Won Kim
Anneli Elme
Zvonko Kusic
Joon Oh Park
Anghel Adrian Udrea
Sun Young Kim
Joong Bae Ahn
Ricardo Villalobos Valencia
Srinivasan Krishnan
Ante Bilic
Nebojsa Manojlovic
Jun Dong
Xuesong Guan
Catherine Lofton-Day
A Scott Jung
Eduard Vrdoljak
British Journal of Cancer, 2016, 115 : 1206 - 1214
[28] Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
Qin, Shukui
Xu, Rui-Hua
Shen, Lin
Xu, Jianming
Bai, Yuxian
Yang, Lei
Deng, Yanhong
Chen, Zhen-dong
Zhong, Haijun
Pan, Hongming
Guo, Weijian
Shu, Yongqian
Yuan, Ying
Zhou, Jianfeng
Xu, Nong
Liu, Tianshu
Ma, Dong
Wu, Changping
Cheng, Ying
Chen, Donghui
Li, Wei
Sun, Sanyuan
Yu, Zhuang
Cao, Peiguo
Chen, Haihui
Wang, Jiejun
Wang, Shubin
Wang, Hongbing
Wang, Ning
Zhang, Bin
Zhang, Qiang
Su, Weiguo
Guo, Xiaojun
Li, Jin
ONCOTARGETS AND THERAPY, 2021, 14 : 4439 - 4450
[29] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study
Lenz, Heinz-Josef
Tabernero, Josep
Yoshino, Takayuki
Lonardi, Sara
Falcone, Alfredo
Miron, Maria Luisa Limon
Saunders, Mark P.
Sobrero, Alberto F.
Park, Young Suk
Monteagudo, Reyes Ferreiro
Hong, Yong Sang
Tomasek, Jiri
Taniguchi, Hiroya
Ciardiello, Fortunato
Sassi, Mouna
Peil, Barbara
Hastedt, Claudia
Studeny, Matus
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[30] A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
Kim, Tae Won
Elme, Anneli
Kusic, Zvonko
Park, Joon Oh
Udrea, Anghel Adrian
Kim, Sun Young
Ahn, Joong Bae
Villalobos Valencia, Ricardo
Krishnan, Srinivasan
Bilic, Ante
Manojlovic, Nebojsa
Dong, Jun
Guan, Xuesong
Lofton-Day, Catherine
Jung, A. Scott
Vrdoljak, Eduard
BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1206 - 1214

← 1 2 3 4 5 →